By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Yeda Research and Development Co., Ltd., v. Doll
1:09-cv-00820; filed May 4, 2009 in the District Court of the District of Columbia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,445,802 ("Site-Specific In Situ Generation of Allicin Using a Targeted Alliinase Delivery System for the Treatment of Cancers, Tumors, Infectious Diseases and Other Allicin-Sensitive Diseases," issued November 4, 2008). View the complaint here.
Monsanto Co. et al. v. E.I. Dupont De Nemours and Co. et al.
4:09-cv-00686; filed May 4, 2009 in the Eastern District of Missouri
Infringement of U.S. Patent No. RE39,247 ("Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate Synthases," issued August 22, 2006) based on defendants' development of a stacked soybean product incorporating Monsanto's Roundup Ready® technology. View the complaint here.
Abbott Biotechnology Ltd. v. Centocor Ortho Biotech, Inc.
4:09-cv-40089; filed May 1, 2009 in the District Court of Massachusetts
Infringement of U.S. Patent No. 7,223,394 ("Human Antibodies that Bind Human TNF alpha," issued May 29, 2007) based on Centocor's imminent launch of it's Simponi product (golimumab, used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis). View the complaint here.
Warner Chilcott Laboratories Ireland Ltd. et al. v. Mylan Pharmaceuticals Inc. et al.
2:09-cv-02073; filed May 1, 2009 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,958,161 ("Modified Release Coated Drug Preparation," issued October 25, 2005) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Warner Chilcott's Doryx® (modified release doxycycline hyclate, used for adjunctive treatment of severe acne). View the complaint here.
Alcon Research Ltd. v. Barr Laboratories Inc.
1:09-cv-00318; filed April 30, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,510,383 ("Use of Cloprostenol, Fluprostenol and Their Salts and Esters to Treat Glaucoma and Ocular Hypertension," issued April 23, 1996), 5,631,287 ("Storage-Stable Prostaglandin Compositions," issued May 20, 1997), 5,849,792 (same title, issued December 15, 1998), 5,889,052 ("Use of Cloprostenol and Fluprostenol Analogues to Treat Glaucoma and Ocular Hypertension," issued March 30, 1999) and 6,011,062 ("Storage-Stable Prostaglandin Compositions," issued January 4, 2000) following a Paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Alcon's Travatan® (travoprost ophthalmic solution, used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertention). View the complaint here.
Pfizer Inc. et al. v. Lupin Ltd. et al.
1:09-cv-01113; filed April 30, 2009 in the District Court of Maryland
Pfizer Inc. et al. v. Sandoz Inc.
3:09-cv-02052; filed April 30, 2009 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 6,001,876 ("Isobutylgaba and Its Derivatives for the Treatment of Pain," issued December 14, 1999), 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers," issued March 6, 2001), and 5,563,175 ("GABA and L-glutamic Acid Analogs for Antiseizure Treatment," issued October 8, 1996) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the Lupin complaint here.
Pfizer Inc. et al. v. Wockhardt Ltd. et al.
3:09-cv-02069; filed April 30, 2009 in the District Court of New Jersey
Pfizer Inc. et al. v. Sun Pharma Global Inc. et al.
3:09-cv-02070; filed April 30, 2009 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers," issued March 6, 2001) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Pfizer's Lyrica® (pregabalin, used to treat fibromyalgia). View the Wockhardt complaint here.
Novartis AG v. Doll
1:09-cv-00804; filed April 20, 2009 in the District Court of the District of Columbia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,446,175 ("Antibodies to human IL-1β," issued November 4, 2008). View the complaint here.
Comments